Artículos del autor

solaci

Coronary Disease

ACC 2022 – EDIT-CMD

Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite...
solaci -
Acute coronary syndromes

ACC 2022 – Complete Trial QoL: Complete Revascularization in STEMI

The COMPLETE study has shown complete revascularization in STEMI reduces cardiovascular mortality or new AMI, which generated...
solaci -
Pharmacology

ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

Roughly 50% of hypertrophic cardiomyopathies (HCM) are obstructive, and of this percentage, most of symptoms can be...
solaci -
Pharmacology

ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac...
solaci -
Institutional News

April 7th | Medtronic-SOLACI Masterclass with Gregg Stone: Revascularization in Patients with Multivessel Lesions

Join us in the third Medtronic-SOLACI masterclass with Dr. Gregg Stone (USA) and renowned Latin-American panelists. In this...
solaci -
Institutional News

19/04 – Cusp Overlap Masterclass with International and LATAM Guests

What is the rationale behind the cusp overlap technique? How should we combine it with commissural alignment...
solaci -
Coronary disease

Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities,...
solaci -
ACC 2022

ACC 2022

Here are the most important scientific articles of the ACC 2022 Congress. If you cannot view the articles,...
solaci -